Richmond Pharmacology, one of the UK’s leading early phase contract research organisations, has opened a new research facility in the heart of central London.
The site, formerly known as Guy’s Drug Research Unit, is strategically placed between Guys and St Thomas hospitals, facilitating easy access to patients and fostering collaboration with these world renowned teaching hospitals. London also offers access to a wide and diverse population allowing effective recruitment of healthy volunteers and patients for early phase clinical trials.
Richmond Pharmacology has already conducted over 300 studies in London since its establishment in 2001, however the new facility will provide a central base for further research programmes to take place, ultimately bringing world leading, early phase clinical trials to patients effectively, and to the global market beyond.
The company specialises in conducting complex and cutting edge trials in crucial disease areas such as oncology and amyloidosis. The company says it conducts approximately 10% of all Phase I studies performed in the UK and 1 in every 100 studies worldwide.
Richmond’s decision to expand its London research footprint was driven by a need to expand its database of volunteers for its model of carrying out trials under one roof rather than in multiple centres.
Commenting, Dr Jorg Taubel, CEO of Richmond Pharmacology said: “The opening of our new research facility, at what was formerly known as the Guy’s Drug Research Unit, is an exciting addition to our research capability, and will help us to provide the best possible support for our clients in their drive to increase the effectiveness and cost efficiency of developing new drugs and taking them to market.“
“The new 54-bed facility will enable Richmond to apply the most up to date research techniques for ground breaking research projects and crucially, at scale – something we think will be highly attractive to our clients in the UK and around the world.”
Sarah Haywood, Chief Executive Officer of Med City UK, representing one of the key businesses in partnership with Richmond Oncology said: “London with 8.3 million NHS patients, a third of which were born overseas, provides an excellent platform for clinical research organisations like Richmond Pharmacology.”
